Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Metastatic Melanoma
and you are
over 18
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

This is a single arm explorative phase II clinical trial in 90 subjects with advanced stage melanoma harbouring a BRAFV600 mutation. PET imaging and molecular diagnostics are combined in order to monitor response to treatment with vemurafenib plus cobimetinib, examine development of resistance and correlate changes in metabolic/proliferative activity with extend of target inhibition.

Provided treatments

  • Drug: Vemurafenib plus cobimetinib
  • Device: Positron Emission Tomography
  • Procedure: Tissue sampling
  • Procedure: Blood sampling
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02414750. The sponsor of the trial is Netherlands Working Group on Immunotherapy of Oncology and it is looking for 90 volunteers for the current phase.
Official trial title:
A Phase II, Open-Label, Multicenter Study of Vemurafenib Plus Cobimetinib (GDC-0973) in Unresectable Stage IIIc or Stage IV Melanoma; Response Monitoring and Resistance Prediction With Positron Emission Tomography and Tumor Characteristics